Flexion Stock Analysis

FLXN -  USA Stock  

USD 5.93  0.06  1.02%

The latest slide in stock price could raise concerns from institutional investors as the firm it trading at a share price of 5.93 on very low momentum in volume. The company executives have failed to build on market volatilities in July. However, diversifying your overall positions with Flexion Therapeutics may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.04. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Flexion Therapeutics partners.
Please check Investing Opportunities.

Search Stock Analysis 

The Flexion Therapeutics stock analysis report makes it easy to digest most publicly released information about Flexion Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Flexion Stock analysis module also helps to analyze the Flexion Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Flexion Stock Analysis Notes

About 90.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.2. Flexion Therapeutics had not issued any dividends in recent years. Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company was founded in 2007 and is headquartered in Burlington, Massachusetts. Flexion Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 257 people. To learn more about Flexion Therapeutics call Michael Clayman at 781 305-7777 or check out www.flexiontherapeutics.com.

Flexion Therapeutics Quarterly Cost of Revenue

6.08 MillionShare

Flexion Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Flexion Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Flexion Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Flexion Therapeutics generates negative expected return over the last 90 days
Flexion Therapeutics has high historical volatility and very poor performance
Flexion Therapeutics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 90.01 M. Net Loss for the year was (105.46 M) with profit before overhead, payroll, taxes, and interest of 66.53 M.
Flexion Therapeutics currently holds about 154.39 M in cash with (60.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.09.
Flexion Therapeutics has a frail financial position based on the latest SEC disclosures
Over 90.0% of the company shares are owned by institutional investors
Latest headline from www.bioworld.com: Bioventus buying Misonix for 518M 2021-07-30 - BioWorld Online

Flexion Therapeutics Upcoming and Recent Events

Earnings reports are used by Flexion Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Flexion Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report4th of August 2021
Next Earnings Report3rd of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End9th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Flexion Largest EPS Surprises

Earnings surprises can significantly impact Flexion Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Flexion Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Flexion Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Flexion Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Flexion Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
12th of July 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
25th of June 2021
Submission of Matters to a Vote of Security Holders
12th of May 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Results of Operations and Financial Condition
11th of May 2021
Financial Statements and Exhibits. Regulation FD Disclosure
10th of May 2021
Unclassified Corporate Event
13th of April 2021
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
5th of April 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
10th of March 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Results of Operations and Financial Condition

Flexion Therapeutics Thematic Classifications

In addition to having Flexion Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products IdeaPharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Flexion Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 306.64 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Flexion Therapeutics's market, we take the total number of its shares issued and multiply it by Flexion Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Flexion Profitablity

Flexion Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Flexion Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Flexion Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Flexion Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Flexion Therapeutics' profitability requires more research than a typical breakdown of Flexion Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (117.16) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (92.85) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.93.
Last ReportedProjected for 2021
Return on Investment(48.89) (52.75) 
Return on Average Assets(0.46) (0.49) 
Return on Average Equity 8.19  8.84 
Return on Invested Capital(0.31) (0.34) 
Return on Sales(1.09) (1.17) 

Management Efficiency

The entity has return on total asset (ROA) of (24.02) % which means that it has lost $24.02 on every $100 spent on asset. This is way below average. Flexion Therapeutics management efficiency ratios could be used to measure how well flexion therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Equity is expected to rise to 8.84 this year, although the value of Return on Investment will most likely fall to (52.75) . Flexion Therapeutics Revenue to Assets are quite stable at the moment as compared to the past year. The company's current value of Revenue to Assets is estimated at 0.37. Total Assets Per Share is expected to rise to 5.23 this year, although the value of Total Assets will most likely fall to about 235.2 M.
Last ReportedProjected for 2021
Book Value per Share(0.37) (0.40) 
Enterprise Value over EBIT(8.05) (8.68) 
Enterprise Value over EBITDA(7.45) (8.04) 
Price to Book Value(34.16) (35.06) 
Tangible Assets Book Value per Share 5.60  5.75 
Enterprise Value669.4 M694 M
Tangible Asset Value251.9 M235.2 M

Technical Drivers

As of the 1st of August, Flexion Therapeutics shows the coefficient of variation of (686.74), and Mean Deviation of 2.4. Flexion Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have analyzed and interpolated nineteen technical drivers for Flexion Therapeutics, which can be compared to its rivals. Please confirm Flexion Therapeutics variance, as well as the relationship between the value at risk and skewness to decide if Flexion Therapeutics is priced favorably, providing market reflects its regular price of 5.93 per share. Given that Flexion Therapeutics has jensen alpha of (0.46), we urge you to verify Flexion Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Flexion Therapeutics Price Movement Analysis

The output start index for this execution was fifty-nine with a total number of output elements of two. The Triangular Moving Average shows Flexion Therapeutics double smoothed mean price over a specified number of previous prices (i.e., averaged twice). View also all equity analysis or get more info about triangular moving average overlap studies indicator.

Flexion Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Flexion Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Flexion Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Flexion Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Flexion Therapeutics Technical and Predictive Indicators

Flexion Therapeutics Forecast Models

Flexion Therapeutics time-series forecasting models is one of many Flexion Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Flexion Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Flexion Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Flexion Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Flexion shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Flexion Therapeutics. By using and applying Flexion Stock analysis, traders can create a robust methodology for identifying Flexion entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(1.05) (1.13) 
Gross Margin 0.78  0.76 
Profit Margin(1.33) (1.44) 
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company was founded in 2007 and is headquartered in Burlington, Massachusetts. Flexion Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 257 people.

Current Flexion Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Flexion analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Flexion analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Flexion Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Flexion analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Flexion stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Flexion Therapeutics, talking to its executives and customers, or listening to Flexion conference calls.
Flexion Analyst Advice Details

Flexion Stock Analysis Indicators

Flexion Therapeutics stock analysis indicators help investors evaluate how Flexion Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Flexion Therapeutics shares will generate the highest return on investment. By understating and applying Flexion Therapeutics stock analysis, traders can identify Flexion Therapeutics position entry and exit signals to maximize returns.
Quick Ratio3.19
Fifty Two Week Low5.90
Revenue Growth22.20%
Shares Short Prior Month7.17M
Average Daily Volume Last 10 Day608.05k
Average Daily Volume In Three Month646.87k
Shares Percent Shares Out13.04%
Gross Margins74.64%
Short Percent Of Float13.65%
Forward Price Earnings-8.08
Float Shares45.04M
Fifty Two Week High14.39
Enterprise Value To Ebitda-6.58
Fifty Day Average8.11
Two Hundred Day Average9.55
Enterprise Value To Revenue5.96
Please check Investing Opportunities. Note that the Flexion Therapeutics information on this page should be used as a complementary analysis to other Flexion Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Flexion Stock analysis

When running Flexion Therapeutics price analysis, check to measure Flexion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Flexion Therapeutics is operating at the current time. Most of Flexion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Flexion Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Flexion Therapeutics' price. Additionally, you may evaluate how the addition of Flexion Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
The market value of Flexion Therapeutics is measured differently than its book value, which is the value of Flexion that is recorded on the company's balance sheet. Investors also form their own opinion of Flexion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Flexion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Flexion Therapeutics' market value can be influenced by many factors that don't directly affect Flexion Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Flexion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Flexion Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Flexion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.